CSI Market
Sign In | Register

Sinovac Biotech Ltd (SVA) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access SVA Annual Cash Flow →
A period-by-period view of cash flow from Sinovac Biotech Ltd to Dec 31 2024 helps clarify how Dec 31 2025's cash position has changed over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		0 0 0 (Dec 31 2024)
Operating Activities
Income-198.84
Depreciation & amortization97.45
Amortization of Other Assets1.33
Increase (Decrease) in Deferred Revenue-1.46
Goodwill, Impairment Loss15.69
Provision For Loan Losses Expensed4.14
Inventories Decrease /-Increase7.58
R & D, Environmental and Other Expense0.00
Gain (Loss) on Sale of Assets and Asset Impairment Charges137.24
Share-based Compensation0.00
Income (Loss) from Equity Method Investments, Net of Dividends or Distributions6.72
Increase (Decrease) in Restricted Cash for Operating Activities0.00
Provision For Doubtful Debts-
Accumulated Depreciation Depletion And Amortization Sale Of Property Plant And Equipment-
Research And Development Expenditures Qualifying For Government Grant-
Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest-
Depreciation Of Property And Equipment And Amortization Of Licenses-
Amortization Of L and Use Right-
Non Cash Operating Lease Expense-
Investment Income Nonoperating-
Increase Decrease In Accounts Payable And Accrued Liabilities And Other Current Liabilities-
Impairment Of Intangible Assets Excluding Goodwill-
Income taxes-267.08
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable24.27
Increase (Decrease) in Accounts Payable and Accrued Liabilities0.00
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets2.10
Other Working Capital-8.74
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-1.16
Discontinued operations0.00
Net Cash flow from Operating Activities-512.18
Investing Activities
Capital Expenditures-49.12
Sale of Capital Items0.41
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Payments To Acquire Equity Securities Fv Ni-
Loan To Service Vendors-
Repayments From Service Vendors-
Loan To Related Parties-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments4,454.14
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired-14.15
Proceeds from Divestiture of Interest in Consolidated Subsidiaries0.18
Sale of businesses0.00
Accounts payable0.00
Payments to Acquire Lease Receivables-0.24
Payments for (Proceeds from) Other Investing Activities0.00
Other Net1.70
Discontinued operations0.00
Net Cash Flow from Investing Activities4,388.17
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings99.64
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Stock Options Exercised With Shares Issued Subsequent To Year End-
Proceeds From Government Grants-
Cash And Cash Equivalents Period Increase Decrease Including Cash Classified Within Current Aseets Held For Sale-
Cash And Cash Equivalents Period Increase Decrease Including Discontiune Operation-
Cash And Cash Equivalents Period Increase Decrease Contiune Operation-
Repayments Of Loan From Noncontrolling Shareholder-
Proceeds From Subsidiaries Financing-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid-3,534.34
Net Cash Flow from Financing Activities-3,434.71
Effect of exchange rate on cash flow112.93
Discontinued operations0.00
Free Cash Flow-560.90
Total Cash Flow554.21
4 historic quarters locked

Sign in to unlock the full Sinovac Biotech Ltd cash flow history.

Sign In Create Free Account

About Sinovac Biotech Ltd Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 20-F filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-258534

Figures are derived from filed reports and may be restated. Historical data is subject to revision.